Agile Therapeutics (NASDAQ:AGRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report published on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a hold rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

Agile Therapeutics Stock Up 3.7 %

Shares of AGRX stock opened at $0.39 on Friday. Agile Therapeutics has a twelve month low of $0.20 and a twelve month high of $7.00. The company has a market cap of $2.70 million, a P/E ratio of -0.04 and a beta of 1.42. The business has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $1.42.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Thursday, March 28th. The specialty pharmaceutical company reported ($1.46) earnings per share for the quarter. The company had revenue of $3.62 million during the quarter.

Hedge Funds Weigh In On Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC boosted its position in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is owned by institutional investors and hedge funds.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.